Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors

This study is a Phase 1 and pharmacologic dose-escalation trial of MM-121 + certain
anticancer therapies. The dose-escalation portion of the study employs a 3 + 3 design to
assess the safety, tolerability, and pharmacokinetics of MM-121 administered weekly in
combination with certain anticancer therapies in patients with advanced/recurrent cancer.
Doses of MM-121 will be escalated when given in combination with a fixed dose of anticancer
therapy in this study until either the MTD is identified or the combination is shown to be
tolerable at the highest planned doses.

Inclusion Criteria:

- Advanced-stage solid tumors

- ≥ 18 years of age

- Adequate liver and kidney function

Exclusion Criteria:

- Any other active malignancy

- No known HIV, Hepatitis C or B